問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

List

1336Cases

2012-05-12 - 2015-05-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-10-01 - 2012-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2010-06-30 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2012-09-01 - 2016-02-28

Phase III

Long-term Extension Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    Schizophrenia

  • Test Drug

    SM-13496

Participate Sites
8Sites

Terminated8Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2012-08-01 - 2015-08-31

Phase III

Randomized, Double-blind, Parallel- group, Placebo-controlled, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    schizophrenia

  • Test Drug

    SM-13496

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2013-03-01 - 2015-07-31

Phase III

A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    MK-3102

Participate Sites
16Sites

Terminated16Sites

2013-12-18 - 2015-10-31

Phase III

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients with Major Depressive Disorder

  • Condition/Disease

    Major depressive disorder

  • Test Drug

    ASC-01

Participate Sites
12Sites

Terminated12Sites

藍先元
China Medical University Hospital

Division of Psychiatry

2013-08-01 - 2015-10-30

Phase III

A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Na&iuml;ve and Treatment-Experienced Korean and Taiwanese Subjects with Chronic Genotype 1 HCV Infection

  • Condition/Disease

    HCV Infection

  • Test Drug

    Sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) tablets

Participate Sites
13Sites

Terminated13Sites

2016-02-15 - 2019-12-31

Phase II

A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    HM61713

Participate Sites
6Sites

Terminated6Sites

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-10-05 - 2015-10-05

Phase II

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis

  • Condition/Disease

    Active Proliferative Lupus Nephritis

  • Test Drug

    Anifrolumab

Participate Sites
6Sites

Terminated6Sites

1 109 110 111 112 113 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB